Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCPH3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,332.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $19,332.22 to DMS Pharmaceutical Group Inc. for Trikafta 100-50-75 mg/150 mg tablets (84-count unit) on January 15, 2026, with an ultimate completion date of January 16, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is issued under the company's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program (contract SPE2DR) with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The contract encompasses a 30-month base period with three 30-month option periods and authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, and medical consumables. This delivery order for Trikafta, a specialty pharmaceutical treatment, exemplifies the vendor's role as a critical supplier within the federal pharmaceutical supply chain supporting military medical operations.
Quick answers
Who was awarded contract SPE2DR26FCPH3?
SPE2DR26FCPH3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FCPH3 worth?
The government has obligated $19,332 on SPE2DR26FCPH3.
Is contract SPE2DR26FCPH3 an order under another contract?
Yes. SPE2DR26FCPH3 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPH3 competed?
The extent of competition for SPE2DR26FCPH3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award